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Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus associated with many malignant and nonma-
lignant human diseases. Life-long latent EBV persistence occurs in blood-borne B lymphocytes, while EBV
intermittently productively replicates in mucosal epithelia. Although several models have previously been
proposed, the mechanism of EBV transition between these two reservoirs of infection has not been determined.
In this study, we present the first evidence demonstrating that EBV latently infects a unique subset of
blood-borne mononuclear cells that are direct precursors to Langerhans cells and that EBV both latently and
productively infects oral epithelium-resident cells that are likely Langerhans cells. These data form the basis
of a proposed new model of EBV transition from blood to oral epithelium in which EBV-infected Langerhans
cell precursors serve to transport EBV to the oral epithelium as they migrate and differentiate into oral
Langerhans cells. This new model contributes fresh insight into the natural history of EBV infection and the
pathogenesis of EBV-associated epithelial disease.
Epstein-Barr virus (EBV) is a human herpesvirus that ulti-
mately infects 95% of adults worldwide. EBV is transmitted via
mucosal fluids and establishes life-long persistent infection.
Although persistent infection is asymptomatic in most people,
EBV is associated with benign syndromes, including infectious
mononucleosis and oral hairy leukoplakia, and a wide variety
of both lymphoid and mucosal epithelial malignancies. Persis-
tent latent EBV infection occurs in memory B lymphocytes
that circulate in blood (22). While latent EBV infection also
occurs in some epithelial malignancies (29), EBV infection of
epithelial cells typically results in productive replication, as
demonstrated in oral hairy leukoplakia (9) and in normal oral
epithelium (8, 10, 48).
Three different models have previously been proposed to
explain the transition of EBV from the latent reservoir of
infection in blood-borne B lymphocytes to sites of productive
replication in oral epithelium. Model 1 proposes that B lym-
phocytes carrying latent EBV infection migrate from the blood
to the epithelium, where the EBV reactivates and infects ad-
jacent epithelial cells (12), but evidence of intraepithelial B
lymphocytes in normal oral epithelium or in oral hairy leuko-
plakia is lacking (30, 33). Model 2 proposes that EBV virions
produced by B lymphocytes in the oral submucosa bind sub-
mucosal EBV-specific dimeric immunoglobulin A (IgA) and
enter basal oral epithelial cells by endocytosis via the polymeric
Ig receptor (37), but the polymeric Ig receptor is not expressed
in oral epithelium (23). Model 3 proposes that EBV virions
produced by B lymphocytes in oral lymphoid tissues (26) gain
access to and infect middle- and upper-layer oral epithelial
cells as a result of microscopic traumatic epithelial injury, such
as that which occurs during mastication. However, this model
is contradicted by evidence that EBV transitions into oral
epithelium as cell-associated latent infection and that EBV
reactivates from a persistent latent oral mucosal source to
productively replicate in the oral epithelium (44, 47, 50).
We now propose a fourth model of EBV transition from
blood into oral epithelium. Langerhans cells (LC) are dendritic
antigen-presenting cells that reside in the basal and suprabasal
layers of cutaneous and mucosal epithelia. Bone marrow-de-
rived LC precursor cells (pre-LC) circulate in the blood before
they migrate into epithelia and differentiate into LC (4). We
hypothesized that EBV latently infects blood-borne pre-LC
and that these EBV-infected pre-LC serve as transporters of
the EBV as they migrate and differentiate into epithelium-
resident LC. EBV reactivation in oral LC could infect adjacent
epithelial cells that could result in productive EBV replication
in the epithelial cells. In this study, we present evidence dem-
onstrating that blood-borne pre-LC are latently infected with
EBV and that oral epithelium cells likely to be LC harbor EBV
infection that can reactivate into productive EBV replication.
MATERIALS AND METHODS
Human research subjects and tissue specimens. Human experimentation re-
search was approved by the University of Texas Medical Branch at Galveston
Institutional Review Board and the University of Texas Health Science Center at
Houston Committee for the Protection of Human Subjects. Informed consent
was obtained from each research subject. Subjects were either healthy individuals
or patients infected with human immunodeficiency virus (HIV), with or without
AIDS. Tissue specimens obtained included 100 ml of venous blood, tongue and
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buccal mucosal epithelium cells collected by nonsurgical oral epithelial brush
biopsy (45), and tongue and buccal mucosal tissue collected by surgical excisional
biopsy (44, 46–48, 50). Some subjects contributed specimens more than once,
and the numerical identity of each subject was maintained throughout the study.
Isolation of pre-LC from blood. Mononuclear cells were isolated from anti-
coagulated whole blood by density gradient centrifugation with Ficoll-Hypaque
and washed and suspended in phosphate-buffered saline. The major cell subsets
were then removed from the mononuclear cell population with mouse monoclo-
nal antibodies against defining human cell surface molecules, followed by mag-
netic separation with sheep monoclonal antibody against mouse IgG conjugated
to magnetic microbeads (Dynabeads; Dynal Biotech, Oslo, Norway) in the fol-
lowing sequence: T lymphocytes (Table 1, antibody 1), B lymphocytes (Table 1,
antibody 2), and monocytes (Table 1, antibody 3). Finally, the CD1a cells were
positively selected and isolated from the remaining mononuclear cells by using
anti-CD1a antibody (Table 1, antibody 4) and magnetic separation with magnetic
microbeads (CELLection Pan Mouse IgG Kit; Dynal Biotech, Oslo, Norway)
and then released from the microbeads with DNase I. Cells were maintained at
4°C throughout the procedure.
Isolation of LC from oral epithelium. Cells obtained with the oral epithelial
biopsy brush were suspended and washed in phosphate-buffered saline. CD1a
cells were positively selected and isolated from the total cell population by using
anti-CD1a antibody (Table 1, antibody 4) and magnetic separation with magnetic
microbeads (CELLection Pan Mouse IgG Kit; Dynal Biotech, Oslo, Norway)
and then released from the microbeads with DNase I and 0.25% trypsin. Cells
were maintained at 4°C throughout the procedure.
Histologic and molecular characterization of oral surgical biopsy tissues. One
half of each surgical biopsy specimen was formalin fixed and paraffin embedded.
Tissue sections were placed on positively charged glass slides, stained with he-
matoxylin and eosin, and examined by an oral and maxillofacial pathologist.
Specimens were classified as oral hairy leukoplakia if they demonstrated hyper-
parakeratosis, acanthosis, “koilocyte”-like cells, nuclear chromatin margination,
and molecular evidence of productive EBV replication. The other half of each
surgical biopsy specimen was frozen, processed for nucleic acid extraction, and
analyzed by reverse transcription (RT)-PCR for CD19, CD45, and EBV gene
expression by using a previously validated molecular definition of productive
EBV replication (45–48, 50).
Culture of LC and chemical induction of EBV. CD1a cells were cultured in
RPMI 1640 medium with 15% fetal bovine serum, penicillin, streptomycin, and
amphotericin B at 37°C in a 5% CO2 atmosphere. Induction of EBV replication
was achieved by adding 30 ng/ml phorbol 12-myristate 13-acetate (MP Biochemi-
cals, Irvine, CA), sodium n-butyrate (Sigma-Aldrich, St. Louis, MO) to a 3 mM
final concentration, and 50 g/ml 5-iodo-2-deoxyuridine (Sigma-Aldrich, St.
Louis, MO) to the medium and incubating it for 48 to 72 h.
Fluorescent immunostaining of cell surface markers. CD1a cells were
stained with fluorochrome-conjugated monoclonal antibodies against cell surface
molecules (Table 1, antibody 5 to 14). Appropriate fluorochrome-conjugated
isotype control antibodies were used. After staining, cells were fixed in 4%
paraformaldehyde and cell staining was analyzed with a FACSort flow cytometer
with CellQuest software (Becton Dickinson, San Jose, CA) or by imaging on a
Zeiss LSM 510 UV META laser scanning confocal microscope.
Limiting-dilution PCR analysis of EBV infection. For each subject, DNA
purified from a known number (x) of CD1a cells was serially diluted into four
sets of 9 or 10 tubes, each tube with the following quantity of DNA: set 1, 0.075 
x cells; set 2, 0.025  x cells; set 3, 0.0075  x cells; set 4, 0.0025  x cells. The
DNA in each tube was then amplified by nested PCR to detect a single-copy
sequence present in the EBV gene for BALF1 (Table 2). Forty cycles each were
performed for the initial reaction with Pfu Turbo Hotstart DNA polymerase
(Stratagene, La Jolla, CA) and for the nested reaction with Vent DNA polymer-
ase (New England BioLabs, Beverly, MA). Amplified products were identified by
agarose gel electrophoresis and Southern blot hybridization to an internal 32P-
labeled oligonucleotide probe as those products consistent with the predicted
size. The sensitivity of this PCR assay was one copy of the target EBV DNA
sequence. Standard techniques were used to prevent and detect in vitro contam-
ination of the amplification reaction mixtures. The fraction of negative tubes
from each set was plotted on a semilog graph versus the number of cells repre-
sented by the DNA added to each tube of the set. The number of cells repre-
sented by the line crossing the 37% EBV-negative point was taken as the number
of CD1a cells harboring a single EBV genome in vivo for each subject. Pooled
TABLE 1. Antibodies used in this study
Antibody Antibody origin Antigen target Conjugate Clone Source
1 Mouse CD3 None HIT3a BD/Pharmingena
2 Mouse CD19 None HIB19 BD/Pharmingen
3 Mouse CD14 None M5E2 BD/Pharmingen
4 Mouse CD1a None HI149 BD/Pharmingen
5 Mouse CD1a FITC WM35 Research Diagnosticsb
6 Mouse CD1a PEf SK9 BD/Pharmingen
7 Mouse CD11c PE B-ly6 BD/Pharmingen
8 Mouse CCR6 PE 11A9 BD/Pharmingen
9 Mouse E-cadherin FITC 36 BD/Pharmingen
10 Mouse CD207/Langerin PE DCGM4 Beckman Coulter Immunotechc
11 Mouse CD21 PE B-ly4 BD/Pharmingen
12 Mouse CD3 PerCPg SK7 BD/Pharmingen
13 Mouse CD19 PE HIB19 BD/Pharmingen
14 Mouse CD14 FITC MP9 BD/Pharmingen
15 Goat FITC Biotin Polyclonal Vector Laboratoriesd
16 Goat Rhodamine Biotin Polyclonal Vector Laboratories
17 Goat CD207/Langerin Biotin Polyclonal R&D Systemse
a BD Biosciences/Pharmingen, San Jose, CA.
b Research Diagnostics, Inc., Flanders, NJ.
c Beckman Coulter Immunotech, Fullerton, CA.
d Vector Laboratories, Inc., Burlingame, CA.
e R&D Systems, Inc., Minneapolis, MN.
f PE, phycoerythrin.
g PerCP, peridinin-chlorophyll-protein complex.
TABLE 2. EBV PCR target gene, primer sequences, and product size
EBV gene Initial primers (5–3) Nested primers (5–3) Final productsize (bp)
BALF1 ATGAGGCCAGCCAAGTCTACA ATGAGGCCAGCCAAGTCTACA
GAACTGACGTCTCAGCGATCT GTCATCCAGGTAGTTTCGCAC 387
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data from all 14 subjects were analyzed by plotting the total fraction of negative
tubes per dilution set versus the total number of cells represented by the DNA
added to the tubes of each dilution set to estimate the population’s mean number
of CD1a cells harboring a single EBV genome in vivo.
Multiplex RT-PCR (M-RT-PCR) analysis of EBV gene expression. RNA pu-
rified from CD1a cells was synthesized into cDNA with an oligo(dT) primer
and an EBER-1 gene-specific primer and then amplified in a multiplexed nested
PCR assay that simultaneously detects seven different EBV gene sequences
(Table 3). Forty cycles each were performed for the initial reaction with Pfu
Turbo Hotstart DNA polymerase (Stratagene, La Jolla, CA) and the nested
reaction with Vent DNA polymerase (New England BioLabs, Beverly, MA).
Amplified products were identified by agarose gel electrophoresis and Southern
blot hybridization to an internal 32P-labeled oligonucleotide probe as those
products consistent with the predicted size. Standard techniques were used to
prevent and detect in vitro contamination of the amplification reaction mixtures.
Fluorescence in situ hybridization (FISH) assay for detection of EBV gene
expression. Formalin-fixed tissue sections and paraformaldehyde-fixed CD1a
cells were placed on positively charged glass slides, deparaffinized with xylene,
rehydrated with decreasing concentrations of ethanol mixed with water, and
permeabilized with Triton X-100, NP-40, and proteinase K. Slides were treated
with 0.25% acetic anhydride in 0.1 M triethanolamine (pH 8.0) and then hybrid-
ized at 55°C for 90 min with four fluorescein isothiocyanate (FITC)-conjugated
peptide nucleic acid oligonucleotides complementary to EBER-1 and EBER-2
transcripts (EBV EBER PNA Probe/FITC; DakoCytomation, Carpinteria, CA)
in a hybridization solution as supplied with the probe, with or without 4 pmol
each of three rhodamine-conjugated locked nucleic acid oligonucleotides com-
plementary to BHLF1 transcripts (Table 4). Slides were washed at 55°C in a
stringent wash solution (PNA ISH Detection Kit; DakoCytomation, Carpinteria,
CA) for 30 min and then blocked with 20% goat serum. Hybridization was
detected with biotin-conjugated goat antibodies against FITC and rhodamine
(Table 1, antibodies 15 to 16) and binding to avidin conjugated to FITC or
rhodamine (Vector Laboratories, Burlingame, CA). For tissue sections, addi-
tional EBER signal amplification was accomplished by a repeat of the biotin
anti-FITC antibody and FITC-avidin. Slides were stained with 4,6-diamidino-
2-phenylindole (DAPI) and analyzed on a Zeiss LSM 510 UV META laser
scanning confocal microscope. Appropriate controls were included with each
batch performance of the protocol.
Fluorescent immunostaining for detection of LC in tissue sections. Formalin-
fixed tissue sections were placed on positively charged glass slides, deparaffinized
with xylene, and rehydrated with decreasing concentrations of ethanol mixed
with water. Antigen unmasking was accomplished by boiling the slides in 10 mM
citric acid (pH 6.0) with 0.05% Tween 20 for 20 min. Tissue sections were
permeabilized with Triton X-100, NP-40, proteinase K, and trypsin. Slides were
blocked with 20% goat serum. LC were detected by using biotin-conjugated goat
antibody against CD207/Langerin (Table 1, antibody 17) and binding to avidin
conjugated to rhodamine (Vector Laboratories, Burlingame, CA). Signal ampli-
fication was accomplished with a biotin-conjugated goat anti-rhodamine anti-
body (Table 1, antibody 16), followed again by rhodamine-avidin. Slides were
stained with DAPI and analyzed on a Zeiss LSM 510 UV META laser scanning
confocal microscope. Appropriate controls were included with each batch
performance of the protocol.
RESULTS
Isolation and characterization of pre-LC from blood. Blood-
borne CD1a CD11c cells are direct precursors of LC, mak-
ing up 0.1 to 0.5% of the total blood mononuclear cell popu-
lation (14). In this study, CD1a mononuclear cells were
isolated from the blood of eight healthy subjects and six with
AIDS to a mean purity of 99% (Table 5). The cumulative mean
frequency of CD3, CD19, and CD14 staining of these
purified cells was 0.7% (range, 0 to 2.5%), with a cumulative
mean frequency for isotype control antibodies of 0.9% (range,
0 to 2.9%). These results demonstrate that CD1a cells were
isolated to near absolute purity without significant contamina-
tion with T lymphocytes, B lymphocytes, or monocytes.
Consistent with the pre-LC phenotype, 97% (mean) of the
CD1a cells coexpressed CD11c, while LC differentiation
markers (E-cadherin, CCR6, CD207/Langerin) and the EBV
TABLE 3. EBV M-RT-PCR target genes, primer sequences, and product sizes
EBV gene Initial primers (5–3) Nested primers (5–3) Spliced transcript finalproduct size (bp)
EBER-1 TACGCTGCCCTAGAGGTTTT TACGCTGCCCTAGAGGTTTT 144a
GGACCACCAGCTGGTACTT CTTGACCGAAGACGGCAGA
BZLF1 ACAGCTAGCAGACATTGGTGT ACAGCTAGCAGACATTGGTGT 223
GCACATCTGCTTCAACAGGAG CCTGTCATTTTCAGATGATTTGG
LMP-2A ACCGTCACTCGGACTATCAA ACCGTCACTCGGACTATCAA 256
AGCTGGCCACTGCTGCCAA GCGGTCACAACGGTACTAA
EBNA-1-Fp/Qpb ATAGCGTGCGCTACCGGATG ATAGCGTGCGCTACCGGATG 333
TATGTCTTGGCCCTGATCCTG CCGTCCTCGTCCATGGTTAT
EBNA-1-Cp/Wpc ACGTGGTGTAAAGTTTTGCCTG ACGTGGTGTAAAGTTTTGCCTG 348
TATGTCTTGGCCCTGATCCTG CCGTCCTCGTCCATGGTTAT
LMP-1 GAGACCTTCTCTGTCCACTTG GAGACCTTCTCTGTCCACTTG 387
GGTAGCTTGTTGAGGGTGCG GTCATCGTGGTGGTGTTCATC
gp220 CAACCTCACCGCACCTGCAA CAACCTCACCGCACCTGCAA 418
GCCGTAATCTGTGGTGGGCT TCCATGTCCTGTGGTGTGCT
a The EBER-1 transcript is not spliced. Control amplification of RNA treated with DNase I but not reverse transcriptase is performed in parallel to exclude the
amplification of possible persisting genomic DNA sequences in the RNA sample.
b EBNA-1 expressed from either the F or the Q promoter.
c EBNA-1 expressed from either the C or the W promoter.
TABLE 4. BHLF1 transcript probe oligonucleotides for EBV
EBER/BHLF1-FISH
Oligonucleotide Sequence (5–3)a
IR2-A ........................................................CGGTGGGTCCGCTGG
IR2-B.........................................................CGCTGGGCACCGCTG
IR2-C.........................................................GGTTCCTGGCGCTCC
a Underlining indicates the bases synthesized by locked nucleic acid chemistry.
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receptor (CD21) were not significantly coexpressed (Table 5).
Cultured CD1a cells markedly up-regulated E-cadherin and
CD207/Langerin expression (Table 6), consistent with a previ-
ous report of culture-induced up-regulation of these LC dif-
ferentiation markers in pre-LC (14).
Cultured CD1a pre-LC evolved from individual round cells
to small cell clusters with short dendritic projections and even-
tually to larger cluster formations with long dendritic projec-
tions that remained stable for more than 10 months (Fig. 1).
The cell clusters likely formed as a result of homotypic inter-
action of newly expressed E-cadherin (31). Immunostaining
confirmed CD1a and CD207/Langerin expression in these cell
clusters (Fig. 1). These culture-induced expression and mor-
phological changes demonstrate that CD1a CD11c cells
purified from blood are, in fact, pre-LC capable of completing
their differentiation into an LC phenotype.
EBV infection in blood-borne pre-LC. To detect EBV infec-
tion in pre-LC, a PCR assay was developed to detect DNA of
the gene for EBV BALF1 with a sensitivity of a single target
copy (Fig. 2). Similar to the approach used to determine the
frequency of EBV infection in B lymphocytes in vivo (22), this
BALF1 PCR assay was applied to limiting dilutions of known
numbers of purified CD1a cells from eight healthy subjects
and six with AIDS to detect EBV genomes (Fig. 2) and to
estimate their frequency in the CD1a cell population. EBV
genomes were detectable in the CD1a cells for 12 of the 14
subjects and in sufficient quantity to estimate their frequency
for 7 of the 14 subjects (Table 7). These seven subjects likely
represent the higher end of the frequency range (highest fre-
quency, 2,200 CD1a cells per EBV genome), whereas insuf-
ficient CD1a cells were available for those subjects in which
EBV infection occurred at the lower end of the frequency
range. To overcome this quantity limitation, pooled data from
all 14 subjects were analyzed collectively to estimate a popu-
lation mean frequency of 12,250 CD1a cells per EBV genome
(Table 7). There was no significant difference in the mean
frequency of CD1a cells per EBV genome between healthy
subjects and those with AIDS (Table 7). Assuming latent EBV
infection with approximately 10 EBV genomes per infected
cell (22), it is estimated that EBV infects approximately 1 cell
in 105 CD1a cells in vivo.
To identify the state of EBV infection in pre-LC, an M-RT-
TABLE 5. Cell surface marker expression in pre-LC newly isolated from blood
Subject or
parameter
(status)a
Mononuclear-cell
yield (108)
CD1a cell
yield (105)
% CD1a
cells
% CD1a
CD11c cells
% CD1a
E-cad cells
% CD1a
CCR6 cells
% CD1a
CD207 cells
% CD1a
CD21 cells
3 (H) 1.72 1.33 98 99 4 0 0 0
4 (H) 1.48 0.89 100 100 3 5 1 0
5 (H) 0.96 0.80 99 100 13 1 3 1
6 (H) 1.27 0.66 98 99 10 8 2 2
7 (H) 1.24 1.25 100 98 16 7 1 1
8 (H) 1.67 1.67 99 99 19 8 1 1
9 (H) 1.47 1.76 99 94 3 2 0 1
10 (H) 1.25 1.87 100 80 1 1 0 1
11 (A) 1.47 2.08 94 100 64 2 1 1
12 (A) 1.81 2.17 100 100 76 1 1 0
13 (A) 1.25 1.50 100 94 5 1 1 4
14 (A) 1.11 1.62 97 98 5 1 1 1
15 (A) 1.85 2.52 98 98 0 2 0 0
16 (A) 1.21 1.81 100 100 1 12 0 0
Mean 1.41 1.56 99 97 16 4 1 1
a H, healthy; A, AIDS.
TABLE 6. Up-regulation of LC differentiation markers in cultured pre-LC
Subject or parameter
and cell status
% CD1a
CD11c cells
% CD1a
E-cad cells
% CD1a
CCR6 cells
% CD1a
CD207 cells
% CD1a
CD21 cells
3
Newly isolated 98 4 0 0 0
Cultured for 3 days 95 76 0 88 0
4
Newly isolated 94 3 5 1 0
Cultured for 3 days 96 67 0 95 0
10
Newly isolated 80 1 1 0 1
Cultured for 3 days 100 42 2 7 3
Mean
Newly isolated 91 3 2 0 0
Cultured for 3 days 97 62 1 63 1
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PCR assay was developed to simultaneously detect the tran-
scription of seven different EBV genes in a single reaction
(EBV M-RT-PCR) such that the EBV gene expression profile
could differentiate among latent infection, nonproductive in-
fection, and productive replication (47, 50). This EBV M-RT-
PCR assay was used to analyze purified CD1a cells from the
blood of the eight healthy subjects and six with AIDS. Expres-
sion of EBER-1 was detected in newly isolated CD1a cells
from 11 subjects and in cultured CD1a cells from 3 of 3
subjects (Fig. 3). Expression of replication-associated BZLF1
was detected in newly isolated CD1a cells from one subject
(Fig. 3). BZLF1 expression was weakly detected in cultured
CD1a cells from three of three subjects and strongly detected
in chemically induced CD1a cells from three of three subjects
(Fig. 3). Expression of LMP-1, LMP-2A, EBNA-1-Fp/Qp,
EBNA-1-Cp/Wp, and gp220 was not detected in the newly
isolated or cultured CD1a cells from any subject. Two sub-
jects showed weak expression of LMP-1 and EBNA-1-Fp/Qp
after chemical induction. These results suggest that EBV in-
fects blood-borne pre-LC as a latency type 0 infection (EBER
only), consistent with latent EBV persistence in a nondividing
cell. The inducible expression of BZLF1, LMP-1, and EBNA-
1-Fp/Qp suggests a potential for EBV in pre-LC to enter a
nonproductive infection state (47, 50).
To confirm the presence of EBER expression in individual
EBV-infected pre-LC, a highly sensitive FISH assay was de-
veloped that is capable of detecting even the lowest level of
EBER transcription found in the Namalwa cell line (2, 38)
(EBER-FISH; Fig. 4) and used to examine purified CD1a
cells from the blood of multiple healthy subjects. In total, two
unequivocally EBER-positive cells were identified (Fig. 4),
each with low-level EBER expression similar to that in the
Namalwa cell line. The rarity of these EBER-FISH-positive
CD1a cells was consistent with the estimated 1-in-105 fre-
quency of EBV pre-LC infection in vivo and confirmed the
EBV M-RT-PCR EBER-1 expression results.
EBV infection in oral epithelial LC. If EBV latently infects
blood-borne pre-LC that will eventually migrate into epithelia
and differentiate into LC, then EBV-infected LC should be
detectable in oral epithelium. To identify EBV infection in oral
LC, an oral epithelial biopsy brush was used to collect cells
from the normal oral epithelium of seven healthy subjects. This
brush obtains cells down to the basal layer, minimizing cells
from the submucosa (45). LC were isolated from the oral cells
by CD1a selection, enriching them to a mean purity of 93%
as defined by coexpression of CD1a and CD207/Langerin. In
newly isolated oral LC, patterns of EBV expression were iden-
tified by EBV M-RT-PCR in two subjects consistent with la-
tent/nonproductive (EBER-1  LMP-1  BZLF1) and super-
imposed productive (EBNA-1-Fp/Qp  EBNA-1-Cp/Wp)
infections (Fig. 5), as previously described for oral EBV infec-
tion (47, 50). Chemically induced oral LC up-regulated EBV
FIG. 1. Differentiation of blood-derived pre-LC into LC during prolonged culture. Examination by light microscopy revealed that most of the
CD1a pre-LC newly isolated from blood were small round cells (black arrows). After 3 days, the number of small round cells decreased and larger
cell clusters with short dendrite-like projections (white arrow) appeared. By 6 weeks, most cell clusters elaborated a large spherical structure of
interlocking dendritic projections surrounding the central core. These structures were stable for more than 10 months of culture and did not
increase in number over time, suggesting a lack of cell division. Fluorescent immunostaining and imaging with a laser scanning confocal microscope
demonstrated expression of both CD1a and CD207/Langerin in these cell clusters, confirming their differentiation into the LC phenotype. Staining
with isotype control fluorescent antibodies was negative. DIC, Nomarski differential interference contrast.
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genes associated with oral productive EBV replication (BZLF1
EBNA-1-Cp/Wp  gp220) (Fig. 5) (47, 48, 50). These re-
sults suggest that EBV infects oral LC primarily as a latent/
nonproductive infection and that EBV in oral LC can reacti-
vate to productive replication.
To detect both latent and replicative EBV infections in oral
epithelium tissues, a highly sensitive FISH assay was developed
to simultaneously detect both EBER and BHLF1 transcription
(EBER/BHLF1-FISH) (Fig. 6) and used to examine 248 tissue
sections from 62 surgical biopsy specimens (29 oral hairy leu-
koplakia, 4 normal epithelium with EBV replication, and 29
normal epithelium without EBV replication) obtained from 28
HIV-positive subjects. Tissues harboring EBV replication hy-
bridized with both EBER and BHLF1 (Fig. 6).
Three examples of solitary intraepithelial cells unequivocally
expressing only EBER were identified (Fig. 6), consistent with
latent EBV infection. The level of EBER expression in each
cell was low, similar to that in the Namalwa cell line. One
example of a solitary intraepithelial cell unequivocally express-
ing both EBER and BHLF1 was identified (Fig. 6), consistent
with EBV reactivation from latency in that cell. No EBV-
positive cells were found in the submucosa of any tissue sec-
tion, and transcription of CD19 and CD45 was not detected in
the tissues with these four EBV-positive cells. All four EBV-
positive cells localized to the basal or lower spinous layer of the
epithelium, the same locations where LC reside (Fig. 7). At-
tempts to combine the EBER/BHLF1-FISH and LC immuno-
staining assays were technically unsuccessful. Nevertheless,
these data demonstrate the presence of rare individual cells in
the lowest layers of oral epithelium that harbor latent EBV
infection and support EBV reactivation.
DISCUSSION
The results of this study demonstrate EBV infection of
blood-borne pre-LC and of oral epithelium cells likely to be
LC. Approximately 1 in 105 pre-LC harbors latent EBV infec-
tion in vivo, a frequency similar to EBV infection of B lym-
phocytes in healthy individuals (6, 22). Blood-borne CD1a
CD11c cells were shown to be pre-LC by their ability to
differentiate into the LC phenotype. Remarkably, the EBV
gene expression patterns, from latency to nonproductive infec-
tion and then productive replication, escalated in parallel with
progression of cell differentiation from blood-borne pre-LC
into oral LC. The nonproductive EBV expression pattern dem-
TABLE 7. EBV genome frequency in pre-LC isolated from blood
Subject or
parameter
(status)a
No. of CD1a cells
available for
PCR assay
Estimated no. of CD1a
cells/EBV genome
in vivo
3 (H) 66,600 IDEc (4,955)
4 (H) 44,500 2,200
5 (H) 40,000 10,750
6 (H) 33,000 IDE (2,475)
7 (H) 62,500 6,300
8 (H) 83,400 3,200
9 (H) 88,200 IDE (6,615)
10 (H) 93,700 EBV NDd
11 (A) 104,200 IDE (7,815)
12 (A) 108,600 IDE (8,145)
13 (A) 75,000 EBV ND
14 (A) 81,000 13,200
15 (A) 125,900 4,700
16 (A) 90,600 13,150
Mean
All subjects NAb 12,250
Healthy subjects NA 8,450
AIDS subjects NA 15,900
a H, healthy; A, AIDS.
b NA, not applicable (pooled data).
c IDE, insufficient data to estimate.
d ND, not detectable.
FIG. 2. Limiting-dilution PCR of the EBV BALF1 gene in pre-LC
isolated from blood. (A) For control cells, variable numbers of cells of
the Namalwa Burkitt’s lymphoma cell line were diluted into a constant
number of cells of the Raji Burkitt’s lymphoma cell line. Each Nama-
lwa cell carries 2 integrated copies of the EBV genome (two copies of
the BALF1 target sequence), whereas each Raji cell carries approxi-
mately 50 copies of an EBV genome with the BALF1 gene target
sequence naturally deleted. After extraction of the DNA from the
admixed cells, PCR amplification was performed in nine identical
reaction tubes at each level of dilution containing the indicated num-
ber of copies of the BALF1 gene target present along with the DNA of
105 Raji cell equivalents. These results demonstrate that the PCR
amplification assay is both sensitive and specific to a single copy of
target sequence. () Control  B958 lymphoblastoid cell line DNA;
() Control  no DNA. (B) Newly isolated pre-LC (representative
subject example). The DNA from a total of 125,900 CD1a cells
(Table 7, AIDS subject 15) was extracted, distributed among nine
identical reaction tubes at each level of dilution containing the indi-
cated number of cell equivalents, and amplified by PCR for the BALF1
gene target sequence. () Control  B958 lymphoblastoid cell line
DNA; () Control  no DNA.
7254 WALLING ET AL. J. VIROL.
onstrated in the purified oral LC matched that originally de-
scribed for EBV infection in normal oral epithelium without
productive replication (47, 48, 50).
Importantly, latent EBV infection and EBV reactivation
were identified in rare individual cells in the lower layers of
oral epithelium. These data confirm the suspected presence of
a cellular reservoir of latent EBV infection in the oral epithe-
lium that serves as a reactivation source for productive EBV
FIG. 3. EBV M-RT-PCR of pre-LC isolated from blood. CD1a pre-LC were isolated from the blood of eight healthy subjects and six with
AIDS, each with fewer than 200 CD4 cells/ml of blood (mean, 70; range, 4 to 164). Cells were studied as newly isolated, after culture for 3 days,
or after culture for 3 days and treatment with chemical inducers of EBV replication for 2 more days. RNA extracted from the cells was studied
by EBV M-RT-PCR amplification and specific probe hybridization. () Control  B958 lymphoblastoid cell line DNA and Akata Burkitt’s
lymphoma cell line DNA; () Control  no DNA. (A) Newly isolated pre-LC. EBER-1 expression was demonstrated in healthy subjects 3, 4, 5,
6, 7, and 10 and in AIDS subjects 11, 12, 14, 15, and 16. With a band in the reverse transcriptase-negative (RT ) reaction mixture, it is uncertain
if the result for subject 6 represents true EBER-1 expression or detection of viral genomic DNA sequences in the RNA preparation. Despite a
band in the reverse transcriptase-negative reaction mixture for subject 13, the absence of a band in the corresponding reverse transcriptase-positive
(RT ) reaction mixture was interpreted as an absence of EBER expression for this subject. (B) Cultured pre-LC. EBER-1 expression was
demonstrated in all three subjects, including subject 8, in whom EBER-1 expression was not detected in newly isolated pre-LC. (C) Control cells.
The EBV-positive Namalwa Burkitt’s lymphoma cell line expresses the least EBER-1 of the known EBV-positive cell lines. The sensitivity of
detection of the EBV M-RT-PCR assay for EBER-1 expression was demonstrated to be a single Namalwa cell diluted into 105 cells of the
EBV-negative RHEK-1 cell line. (D) Newly isolated pre-LC. BZLF1 expression was demonstrated in healthy subject 4. (E) Cultured pre-LC. New
weak BZLF1 expression was demonstrated in all three healthy subjects in whom BZLF1 expression was not detected in newly isolated pre-LC.
(F) Cultured and induced pre-LC. Newly induced strong BZLF1 expression was demonstrated in all three healthy subjects in whom BZLF1
expression was not detected in newly isolated pre-LC.
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FIG. 4. EBV EBER-FISH of pre-LC isolated from blood. Control cells and purified CD1a pre-LC isolated from the blood of healthy subjects
were examined by in situ hybridization for latency-associated EBER transcription. Cells were imaged by fluorescent laser scanning confocal
microscopy. DIC, Nomarski differential interference contrast. (A) EBV-positive Raji Burkitt’s lymphoma cells express high levels of EBER (up
to 105 or 106 transcripts per cell). Nuclear saturation of fluorescence was consistently detected. (B) EBV-positive Namalwa Burkitt’s lymphoma
cells express much lower levels of EBER (at least 100-fold lower than Raji cells). Variable levels of nuclear EBER expression were easily detected
in most Namalwa cells. (C) EBV-negative BJAB Burkitt’s lymphoma cells did not show EBER hybridization. (D) EBV-negative RHEK-1 epithelial
7256 WALLING ET AL. J. VIROL.
cells did not show EBER hybridization. (E) Nuclear EBER expression was detected in a newly isolated CD1a pre-LC. The numerous black circles
represent antibody-conjugated magnetic microbeads that are still attached to most of the CD1a cells, including the EBER-positive cell. (F)
Nuclear EBER expression was detected in a CD1a pre-LC that was cultured in vitro for 3 days before EBER in situ hybridization.
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replication (44, 47, 50). Although multiple previous studies
have failed to identify EBV in the lower layers of oral epithe-
lium (21, 24, 25, 28, 32, 40, 48, 50–52), the singular success of
this study is likely a result of two important methodological
advantages. First, the uniquely high sensitivity of the EBER/
BHLF1-FISH assay made it possible to detect the lowest levels
of EBER expression. Second, examination of an unprece-
dented number of tissue sections, 248, greatly increased the
odds of finding the rare (1 in 105) oral LC expected to harbor
EBV infection.
Although the present data cannot prove that the four soli-
tary EBV-positive cells identified in this study are LC, they are
likely to be LC for the following reasons. EBV latently infects
blood-borne pre-LC that are known to migrate to epithelia and
differentiate into LC. The lower-layer epithelium locations of
the four EBV-positive cells are consistent with the known
localization of oral LC. The four EBV-positive cells are soli-
tary, suggesting that they are nondividing cells, consistent
with known LC biology. If EBV latently infected a basal
epithelial stem or transit amplifying cell, the EBV would be
passed to all progeny cells and EBER in situ hybridization
would identify a cluster of EBV-positive cells instead. Fi-
nally, LC are the most abundant immune cells found in the
oral epithelium. Based upon the absence of CD19 and CD45
expression in these tissues and upon current knowledge of
EBV and epithelial biology, it is unlikely that a rare oral
epithelium-resident B-lymphocyte, T-lymphocyte, melano-
cyte, or Merkel cell would be harboring the EBV identified
in these four cells, but this possibility cannot be absolutely
excluded by present data.
While the results of this study do not directly discredit any of
the three previously proposed models, they are most consistent
with a new model of EBV oral epithelial entry, persistence, and
reactivation based upon EBV infection of blood-borne pre-LC
(Fig. 8). Although only 1% of pre-LC expressed the CD21
EBV receptor (Table 5), this frequency is 1,000-fold higher
than the 1 in 105 pre-LC that apparently becomes infected with
EBV in vivo. Given that productive EBV replication in blood-
borne, EBV-infected B lymphocytes is rare (3, 6), the source of
the EBV that infects blood-borne pre-LC is uncertain. CD21 is
expressed on upper spinous epithelial cells of nonkeratinized
and parakeratinized oral epithelium but not on lower spinous
or basal epithelial cells (5, 40). EBV produced in a basal LC
could access the CD21-positive epithelial cells if virions were
released from dendritic projections extending into the upper
spinous layer. Alternatively, EBV could infect epithelial cells
through a CD21-independent mechanism, such as virion bind-
ing to cellular integrins (41) or direct cell-to-cell transfer (12),
with subsequent lateral spread of EBV infection to adjacent
epithelial cells (41). The resulting EBV replication in the up-
per spinous layer could then occur as either a localized focus in
normal oral epithelium (8, 10, 48) or a wider band-like distri-
bution in oral hairy leukoplakia (9).
The results of this study are consonant with the hypothesis
that productive EBV replication in oral epithelium is the major
source of virus in oral secretions (15). Although EBV replica-
tion has been detected in occasional tonsillar crypt B lympho-
cytes (1, 11, 26, 27), it is uncertain if so few cells can account
for the high levels of virus often detected in saliva (19, 42).
EBV transition into oral epithelium via pre-LC and subse-
quent replication at multiple oral epithelial foci would serve as
a viral production amplifier, achieving greater quantities in
saliva and more efficient transmission.
The results of this study are also consonant with the ob-
served transition of multiple EBV strains from blood to oral
epithelium (44) and the continuously evolving populations of
multiple EBV strains seen in the oral secretions of healthy
persons (34, 42) and mononucleosis patients (7, 35) and in oral
FIG. 5. EBV M-RT-PCR of LC isolated from oral epithelium.
CD1a LC were isolated from cells obtained by brush biopsy of grossly
normal oral mucosal epithelia of seven healthy subjects. Half of each
oral LC specimen was studied as newly isolated cells, and the other half
was studied after culture of the cells in the presence of chemical
inducers of EBV replication for 3 days. RNA extracted from the cells
was studied by EBV M-RT-PCR amplification and specific probe hy-
bridization. () Control  B958 lymphoblastoid cell line DNA and
Akata Burkitt’s lymphoma cell line DNA; () Control  no DNA.
(A) Newly isolated oral LC. EBER-1, BZLF1, EBNA-1-Fp/Qp, and
EBNA-1-Cp/Wp expression was demonstrated in subjects 10 and 20.
LMP-1 expression was demonstrated in subject 10. LMP-2A and gp220
expression was not detected. RT , with reverse transcriptase; RT ,
without reverse transcriptase. (B) Cultured and induced oral LC.
Newly induced BZLF1 expression was demonstrated in subjects 4, 5,
17, 18, and 21 and was especially strong in subject 5. (Note that the
PCR product of subject 10 leaked from the well of the gel, explaining
the apparent lack of BZLF1 hybridization for the induced cells of that
subject, and that BZLF1 expression was also previously detected in
subject 20 prior to induction.) Newly induced LMP-2A and EBNA-1-
Cp/Wp expression was demonstrated in subjects 5 and 18. Newly in-
duced strong gp220 expression was demonstrated in subject 5. LMP-1
and EBNA-1-Fp/Qp expression was not detected.
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FIG. 6. EBV EBER/BHLF1-FISH of oral epithelial tissue. Control cells and oral surgical biopsy tissue sections from HIV-positive subjects were
examined by in situ hybridization for latency-associated EBER transcription and replication-associated BHLF1 transcription. Tissues were imaged by
fluorescence laser scanning confocal microscopy. Tissue section panels are oriented with the mucosal surface to the top. DIC, Nomarski differential
interference contrast. (A) EBV-positive B958 lymphoblastoid cells express high levels of EBER in most cells, and nuclear saturation of fluorescence was
consistently detected. Approximately 1 to 5% of B958 cells also express replicative genes, including the early replicative gene BHLF1. Two different
patterns of nuclear fluorescence were seen with BHLF1 expression, diffuse and punctate. (B) EBV-positive Namalwa Burkitt’s lymphoma cells express
much lower levels of EBER (at least 100-fold lower than B958 cells). Variable levels of nuclear EBER expression were easily detected in most Namalwa
cells, but BHLF1 expression was not detected in these cells, which harbor only latent EBV infection. (C) EBV-negative RHEK-1 epithelial cells did not
hybridize to either EBER or BHLF1. (D) Hybridization with both the EBER and BHLF1 probes was seen in a band-like pattern in the upper spinous
layer of oral hairy leukoplakia, consistent with the known localization of productive EBV replication in the oral epithelium. (E, F, G, and H) Nuclear
EBER probe hybridization was always associated with nuclear cohybridization of the BHLF1 probe in the upper spinous layer of oral hairy leukoplakia.
Nuclear chromatin margination was present, and the most intense EBER probe hybridization strongly colocalized with the BHLF1 probe in the punctate
hybridization pattern. This phenomenon of EBER probe hybridization in the upper spinous layer of oral hairy leukoplakia does not represent latent EBV
infection but instead is consistent with EBER probe cross-hybridization to EBER gene sequences present in single-stranded EBV DNA synthesized in
the nuclei of these cells during productive EBV replication, as previously described for EBER in situ hybridization in oral hairy leukoplakia (28). In the
cells with the strongest nuclear EBER hybridization, additional weaker EBER hybridization was often seen in the cytoplasm and likely represents EBER
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probe cross-hybridization to EBER gene sequences present in artifactually denatured double-stranded EBV DNA in maturing virions being prepared for release
from the cells. Furthermore, the cells immediately below and immediately above the EBER-BHLF1 cohybridizing cells often showed nuclear hybridization with
only the BHLF1 probe. This result is consistent with early gene expression both preceding and persisting after viral DNA synthesis in the differentiation-
dependent cascade of replicative EBV gene expression in oral epithelium, as previously described in oral hairy leukoplakia (40, 52). (I, J, and K) Three tissue
sections (panel I, normal tongue epithelium without EBV replication; panels J and K, tongue epithelium with oral hairy leukoplakia) each demonstrated a solitary
EBER-expressing cell located in or immediately above the basal layer. The locations of the epithelial basement membrane and basal layer are illustrated by the
white lines and circles. The tissue section in panel K represents a cut through the mucosal rete ridges (white circles) in a plane that is
perpendicular to the plane represented by the tissue sections in panels I and J. In all three cases, the EBER probe localization was confirmed
to be intranuclear in a single cell by computer-generated three-dimensional reconstruction of the cell with a sequential series of 0.6-m-deep
confocal microscopy images. This expression of EBER in the absence of BHLF1 indicates the presence of latent EBV infection in each of
these three solitary cells, similar to that demonstrated in the Namalwa cell line (panel B). (L) A tissue section of tongue epithelium with
oral hairy leukoplakia demonstrated a solitary EBER- and BHLF1-coexpressing cell in the basal or lower spinous epithelial layer. The
location of the epithelial basement membrane is not evident in this photomicrograph, but the cell appears to be located at the top of a rete
ridge and was distinctly distant from the EBV replication in the upper spinous epithelial layer. The punctate nuclear colocalization of BHLF1
with the more diffuse EBER and the absence of EBER in the cell cytoplasm together suggest that this cell represents EBV reactivation of
early replicative gene expression in a previously latently infected cell, similar to that demonstrated in the B958 cell line (panel A).
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hairy leukoplakia tissues (43, 44, 47). Given that pre-LC ap-
pear to be inhibited from entering the oral hairy leukoplakia
lesion (46), the EBV-positive cells found in the lower layers of
oral hairy leukoplakia tissue (Fig. 6J to L) likely entered prior
to development of the lesion. Thus, EBV reactivation in oral
LC could not only give rise to new epithelial EBV replication
but also potentially contribute new EBV strains to preexisting
epithelial EBV replication (Fig. 6L).
Interestingly, the frequency of pre-LC EBV infection did
not significantly differ between healthy subjects and those
with AIDS (Table 7), despite a large difference in oral hairy
leukoplakia prevalence between healthy and immunocom-
FIG. 7. CD207/Langerin immunostaining of LC in oral epithelial tissue. Oral surgical biopsy tissue sections of normal tongue epithelium were
immunostained for CD207/Langerin. Tissues were imaged by fluorescent laser scanning confocal microscopy. Tissue section panels are oriented
with the mucosal surface to the top. DIC, Nomarski differential interference contrast. LC were identified in the basal layer and the immediate
suprabasal region of the lower spinous layer of the oral epithelium. The location of the epithelial basement membrane and basal layer is illustrated
by the white lines. These results demonstrate that oral LC localize to the same lower epithelial layers as the solitary EBV-positive cells identified
in Fig. 6, suggesting a possible LC identity for these EBV-positive cells.
FIG. 8. Proposed model of EBV oral epithelial entry, persistence, and reactivation. EBV latently infects pre-LC in the blood. The pre-LC
migrate from the blood, through the submucosa, and into the oral epithelium, transporting latent EBV infection. In the epithelium, the
pre-LC differentiate into LC that reside in the lower epithelial layers and extend dendrites into the upper spinous layer. EBV may persist
in LC as a latent infection or may reactivate in LC to productive replication. Infection of adjacent epithelial cells results in productive EBV
replication in the upper spinous layer, sometimes causing the pathological changes of oral hairy leukoplakia and ultimately releasing
infectious virions into the oral cavity.
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promised persons (9, 17, 20). This result suggests that the
conversion of a focus of EBV replication in normal oral
epithelium into an oral hairy leukoplakia lesion depends
more upon local epithelial immune deficiencies (18), EBV
mechanisms of immune evasion (46), and specific EBV gene
expression patterns (48, 50) than upon the frequency with
which one or more EBV strains enter and reactivate within
the oral epithelium (44, 47).
Finally, the results of this study have implications for
understanding the pathogenesis of other EBV-associated
epithelial diseases. EBV-infected pre-LC likely migrate to
all types of epithelial tissues with equal affinity, but the
probability of EBV reactivation in an epithelial LC and the
outcome of subsequent EBV infection of an epithelial cell
may be determined by the local environment unique to each
type of epithelium. It makes biological sense that EBV is
produced and shed from those mucosal epithelial surfaces
with the greatest potential for transmission of EBV to new
hosts, such as oropharyngeal (19, 42), genital (13, 36), and
lactating mammary (16) epithelia. Other types of mucosal
epithelia may be less permissive of EBV replication and
more susceptible to latent transforming EBV infection, such
as nasopharyngeal (29) and gastric (39) epithelia. The rarity
of finding EBV directly in cutaneous epithelial disease (49)
suggests that epidermal cells may be resistant to both latent
and productive EBV infections.
ACKNOWLEDGMENT
This work was supported in part by a grant from the John Sealy
Memorial Endowment Fund for Biomedical Research to Dennis M.
Walling.
REFERENCES
1. Anagnostopoulos, I., M. Hummel, C. Kreschel, and H. Stein. 1995. Mor-
phology, immunophenotype, and distribution of latently and/or productively
Epstein-Barr virus-infected cells in acute infectious mononucleosis: implica-
tions for the interindividual infection route of Epstein-Barr virus. Blood
85:744–750.
2. Arrand, J. R. 2000. Expressed but enigmatic RNAs. EBV Rep. 7:145–149.
3. Babcock, G. J., L. L. Decker, R. B. Freeman, and D. A. Thorley-Lawson.
1999. Epstein-Barr virus-infected resting memory B cells, not proliferating
lymphoblasts, accumulate in the peripheral blood of immunosuppressed
patients. J. Exp. Med. 190:567–576.
4. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B.
Pulendran, and K. Palucka. 2000. Immunobiology of dendritic cells. Annu.
Rev. Immunol. 18:767–811.
5. Corso, B., L. R. Eversole, and L. Hutt-Fletcher. 1989. Hairy leukoplakia:
Epstein-Barr virus receptors on oral keratinocyte plasma membranes. Oral
Surg. Oral Med. Oral Pathol. 67:416–421.
6. Decker, L. L., L. D. Klaman, and D. A. Thorley-Lawson. 1996. Detection of
the latent form of Epstein-Barr virus DNA in the peripheral blood of healthy
individuals. J. Virol. 70:3286–3289.
7. Fafi-Kremer, S., P. Morand, J. P. Brion, P. Pavese, M. Baccard, R. Germi,
O. Genoulaz, S. Nicod, M. Jolivet, R. W. Ruigrok, J. P. Stahl, and J. M.
Seigneurin. 2005. Long-term shedding of infectious Epstein Barr virus after
infectious mononucleosis. J. Infect. Dis. 191:985–989.
8. Frangou, P., M. Buettner, and G. Niedobitek. 2005. Epstein-Barr virus
(EBV) infection in epithelial cells in vivo: rare detection of EBV replication
in tongue mucosa but not in salivary glands. J. Infect. Dis. 191:238–242.
9. Greenspan, J. S., D. Greenspan, E. T. Lennette, D. I. Abrams, M. A. Conant,
V. Petersen, and U. K. Freese. 1985. Replication of Epstein-Barr virus within
the epithelial cells of oral “hairy” leukoplakia, an AIDS-associated lesion.
N. Engl. J. Med. 313:1564–1571.
10. Herrmann, K., P. Frangou, J. Middeldorp, and G. Niedobitek. 2002.
Epstein-Barr virus replication in tongue epithelial cells. J. Gen. Virol. 83:
2995–2998.
11. Hudnall, S. D., Y. Ge, L. Wei, N.-P. Yang, H.-Q. Wang, and T. Chen. 2005.
Distribution and phenotype of Epstein-Barr virus-infected cells in human
pharyngeal tonsils. Mod. Pathol. 18:519–527.
12. Imai, S., J. Nishikawa, and K. Takada. 1998. Cell-to-cell contact as an
efficient mode of Epstein-Barr virus infection of diverse human epithelial
cells. J. Virol. 72:4371–4378.
13. Israele, V., P. Shirley, and J. W. Sixbey. 1991. Excretion of the Epstein-Barr
virus from the genital tract of men. J. Infect. Dis. 163:1341–1343.
14. Ito, T., M. Inaba, K. Inaba, J. Toki, S. Sogo, T. Iguchi, Y. Adachi, K.
Yamaguchi, R. Amakawa, J. Valladeau, S. Saeland, S. Fukuhara, and S.
Ikehara. 1999. A CD1a/CD11c subset of human blood dendritic cells is a
direct precursor of Langerhans cells. J. Immunol. 163:1409–1419.
15. Jiang, R., R. S. Scott, and L. M. Hutt-Fletcher. 2006. Epstein-Barr virus shed
in saliva is high in B-cell-tropic glycoprotein gp42. J. Virol. 80:7281–7283.
16. Junker, A. K., E. E. Thomas, A. Radcliffe, R. B. Forsyth, A. G. Davidson, and
L. Rymo. 1991. Epstein-Barr virus shedding in breast milk. Am. J. Med. Sci.
302:220–223.
17. King, G. N., C. M. Healy, M. T. Glover, J. T. Kwan, D. M. Williams, I. M.
Leigh, and M. H. Thornhill. 1994. Prevalence and risk factors associated with
leukoplakia, hairy leukoplakia, erythematous candidiasis, and gingival hy-
perplasia in renal transplant recipients. Oral Surg. Oral Med. Oral Pathol.
78:718–726.
18. Lilly, E. A., J. E. Cameron, K. V. Shetty, J. E. Leigh, S. Hager, K. M.
McNulty, C. Cheeks, M. E. Hagensee, and P. L. Fidel, Jr. 2005. Lack of
evidence for local immune activity in oral hairy leukoplakia and oral wart
lesions. Oral Microbiol. Immunol. 20:154–162.
19. Ling, P. D., J. A. Lednicky, W. A. Keitel, D. G. Poston, Z. S. White, R. Peng,
Z. Liu, S. K. Mehta, D. L. Pierson, C. M. Rooney, R. A. Vilchez, E. O. Smith,
and J. S. Butel. 2003. The dynamics of herpesvirus and polyomavirus reac-
tivation and shedding in healthy adults: a 14-month longitudinal study. J. In-
fect. Dis. 187:1571–1580.
20. Lozada-Nur, F., J. Robinson, and J. A. Regezi. 1994. Oral hairy leukoplakia
in nonimmunosuppressed patients. Report of four cases. Oral Surg. Oral
Med. Oral Pathol. 78:599–602.
21. Miller, D. R., P. L. Heard, M. P. Cagle, D. DiMaio, Y. Ench, D. G. Morrison,
P. A. Eagan, M. L. Gulley, H. B. Jenson, and M. P. Moyer. 1994. Absence of
a reservoir of Epstein-Barr virus (EBV) in normal tongue epithelium. J. Oral
Pathol. Med. 23:156–160.
22. Miyashita, E. M., B. Yang, K. M. Lam, D. H. Crawford, and D. A. Thorley-
Lawson. 1995. A novel form of Epstein-Barr virus latency in normal B cells
in vivo. Cell 80:593–601.
23. Mogi, G. 1975. Secretory immunoglobulin A in oral and respiratory passages
in man. Ann. Otol. Rhinol. Laryngol. 84:1–23.
24. Murray, P. G., G. Niedobitek, E. Kremmer, F. Grasser, G. M. Reynolds, A.
Cruchley, D. M. Williams, N. Muller-Lantzsch, and L. S. Young. 1996. In
situ detection of the Epstein-Barr virus-encoded nuclear antigen 1 in oral
hairy leukoplakia and virus-associated carcinomas. J. Pathol. 178:44–47.
25. Murray, P. G., L. J. Swinnen, C. M. Constandinou, J. M. Pyle, T. J. Carr,
J. M. Hardwick, and R. F. Ambinder. 1996. BCL-2 but not its Epstein-Barr
virus-encoded homologue, BHRF1, is commonly expressed in posttransplan-
tation lymphoproliferative disorders. Blood 87:706–711.
26. Niedobitek, G., A. Agathanggelou, N. Steven, and L. S. Young. 2000. Epstein-
Barr virus (EBV) in infectious mononucleosis: detection of the virus in
tonsillar B lymphocytes but not in desquamated oropharyngeal epithelial
cells. Mol. Pathol. 53:37–42.
27. Niedobitek, G., A. Agathanggelou, H. Herbst, L. Whitehead, D. H. Wright,
and L. S. Young. 1997. Epstein-Barr virus (EBV) infection in infectious
mononucleosis: viral latency, replication and phenotype of EBV-infected
cells. J. Pathol. 182:151–159.
28. Niedobitek, G., L. S. Young, R. Lau, L. Brooks, D. Greenspan, J. S. Greenspan,
and A. B. Rickinson. 1991. Epstein-Barr virus infection in oral hairy leukoplakia:
virus replication in the absence of a detectable latent phase. J. Gen. Virol.
72:3035–3046.
29. Pathmanathan, R., U. Prasad, R. Sadler, K. Flynn, and N. Raab-Traub.
1995. Clonal proliferations of cells infected with Epstein-Barr virus in pre-
invasive lesions related to nasopharyngeal carcinoma. N. Engl. J. Med. 333:
693–698.
30. Riccardi, R., N. Pimpinelli, G. Ficarra, L. Borgognoni, D. Gaglioti, D. Milo,
and P. Romagnoli. 1990. Morphology and membrane antigens of nonlym-
phoid accessory cells in oral hairy leukoplakia. Hum. Pathol. 21:897–904.
31. Riedl, E., J. Stockl, O. Majdic, C. Scheinecker, K. Rappersberger, W. Knapp,
and H. Strobl. 2000. Functional involvement of E-cadherin in TGF-	1-
induced cell cluster formation of in vitro developing human Langerhans-type
dendritic cells. J. Immunol. 165:1381–1386.
32. Sandvej, K., L. Krenacs, S. J. Hamilton-Dutoit, J. L. Rindum, J. J. Pindborg,
and G. Pallesen. 1992. Epstein-Barr virus latent and replicative gene expres-
sion in oral hairy leukoplakia. Histopathology 20:387–395.
33. Se´guier, S., G. Godeau, and N. Brousse. 2000. Immunohistological and
morphometric analysis of intra-epithelial lymphocytes and Langerhans cells
in healthy and diseased human gingival tissues. Arch. Oral Biol. 45:441–452.
34. Sitki-Green, D., M. Covington, and N. Raab-Traub. 2003. Compartmental-
ization and transmission of multiple Epstein Barr virus strains in asymptom-
atic carriers. J. Virol. 77:1840–1847.
35. Sitki-Green, D. L., R. H. Edwards, M. M. Covington, and N. Raab-Traub.
2004. Biology of Epstein-Barr virus during infectious mononucleosis. J. In-
fect. Dis. 189:483–492.
VOL. 81, 2007 EBV IN PRE-LC TRANSITIONS FROM BLOOD TO EPITHELIA 7267
36. Sixbey, J. W., S. M. Lemon, and J. S. Pagano. 1986. A second site for
Epstein-Barr virus shedding: the uterine cervix. Lancet 2:1122–1124.
37. Sixbey, J. W., and Q. Y. Yao. 1992. Immunoglobulin A-induced shift of
Epstein-Barr virus tissue tropism. Science 255:1578–1580.
38. Stowe, R. P., M. L. Cubbage, C. F. Sams, D. L. Pierson, and A. D. Barrett.
1998. Detection and quantification of Epstein-Barr virus EBER1 in EBV-
infected cells by fluorescent in situ hybridization and flow cytometry. J. Virol.
Methods 75:83–91.
39. Takada, K. 2000. Epstein-Barr virus and gastric carcinoma. Mol. Pathol.
53:255–261.
40. Thomas, J. A., D. H. Felix, D. Wray, J. C. Southam, H. A. Cubie, and D. H.
Crawford. 1991. Epstein-Barr virus gene expression and epithelial cell dif-
ferentiation in oral hairy leukoplakia. Am. J. Pathol. 139:1369–1380.
41. Tugizov, S. M., J. W. Berline, and J. M. Palefsky. 2003. Epstein-Barr virus
infection of polarized tongue and nasopharyngeal epithelial cells. Nat. Med.
9:307–314.
42. Walling, D. M., A. L. Brown, W. Etienne, W. A. Keitel, and P. D. Ling. 2003.
Multiple Epstein-Barr virus infections in healthy individuals. J. Virol. 77:
6546–6550.
43. Walling, D. M., S. N. Edmiston, J. W. Sixbey, M. Abdel-Hamid, L. Resnick,
and N. Raab-Traub. 1992. Coinfection with multiple strains of the Epstein-
Barr virus in human immunodeficiency virus-associated hairy leukoplakia.
Proc. Natl. Acad. Sci. USA 89:6560–6564.
44. Walling, D. M., W. Etienne, A. J. Ray, C. M. Flaitz, and C. M. Nichols. 2004.
Persistence and transition of Epstein-Barr virus genotypes in the pathogen-
esis of oral hairy leukoplakia. J. Infect. Dis. 190:387–395.
45. Walling, D. M., C. M. Flaitz, K. Adler-Storthz, and C. M. Nichols. 2003. A
non-invasive technique for studying oral epithelial Epstein-Barr virus infec-
tion and disease. Oral Oncol. 13:436–444.
46. Walling, D. M., C. M. Flaitz, F. G. Hosein, M. Montes-Walters, and C. M.
Nichols. 2004. Effect of Epstein-Barr virus replication on Langerhans cells in
pathogenesis of oral hairy leukoplakia. J. Infect. Dis. 189:1656–1663.
47. Walling, D. M., C. M. Flaitz, and C. M. Nichols. 2003. Epstein-Barr virus
replication in oral hairy leukoplakia: response, persistence, and resistance to
treatment with valacyclovir. J. Infect. Dis. 188:883–890.
48. Walling, D. M., C. M. Flaitz, C. M. Nichols, S. D. Hudnall, and K. Adler-
Storthz. 2001. Persistent productive Epstein-Barr virus replication in normal
epithelial cells in vivo. J. Infect. Dis. 184:1499–1507.
49. Walling, D. M., S. D. Hudnall, and A. Yen-Moore. 2002. Epstein-Barr virus,
p. 145–171. In S. K. Tyring (ed.), Mucocutaneous manifestations of viral
diseases. Marcel Dekker, Inc., New York, NY.
50. Walling, D. M., P. D. Ling, A. V. Gordadze, M. Montes-Walters, C. M. Flaitz,
and C. M. Nichols. 2004. Expression of Epstein-Barr virus latent genes in
oral epithelium: determinants of the pathogenesis of oral hairy leukoplakia.
J. Infect. Dis. 190:396–399.
51. Webster-Cyriaque, J., J. Middeldorp, and N. Raab-Traub. 2000. Hairy leu-
koplakia: an unusual combination of transforming and permissive Epstein-
Barr virus infections. J. Virol. 74:7610–7618.
52. Young, L. S., R. Lau, M. Rowe, G. Niedobitek, G. Packham, F. Shanahan,
D. T. Rowe, D. Greenspan, J. S. Greenspan, A. B. Rickinson, and P. J.
Farrell. 1991. Differentiation-associated expression of the Epstein-Barr virus
BZLF1 transactivator protein in oral hairy leukoplakia. J. Virol. 65:2868–
2874.
7268 WALLING ET AL. J. VIROL.
